$LEAS Major Pharma Potential with Acquisitions lined up PT .50
PHARMIA’s $LEAS goal is to become a leading generics and super-generics company within 5 years. In executing its Plan, PHARMIA will take a three stage approach to the achievement of its goals.
Stage 1
In the initial stage, PHARMIA will launch the company by acquiring MAs in Europe and ANDAs in the United States for generic products that are essential medicines in chronic short supply. PHARMIA will use 3rd parties in Germany to manufacture our oncology products and we will commercialize these “supply challenged” products which generally are older but “mainstay” life-saving medications for the treatment of cancer and infectious diseases, to include the drug shortages caused by the COVID-19 pandemic, where PHARMIA’s team has particular expertise. We will build the drug portfolio and the PHARMIA “brand name” during Stage 1.
Stage 2
In the second stage of PHARMIA’s strategic plan, the company will develop and commercialize a portfolio of novel branded “super-generics” (super-generics are “better than generics” as they have added value and are patented). To achieve this goal, PHARMIA will capitalize on its ownership of the active pharmaceutical ingredients (“API”) acquired in Stage 1, and utilize the scientific and technical development expertise of its team members to reformulate the API of those generics into patented formulations. The goal is to create novel, patentable formulations with novel and improved characteristics (such as extended release, dissolvable films and implants, multiple drug combinations in one pill, etc.) that are more patient friendly, and more easily administered. The development of a portfolio of “super-generics” during Stage 2 will be a major revenue driver going forward. This “value add” will enhance patient compliance and therapeutic outcomes, differentiating PHARMIA pipeline from the competition. Also during Stage 2, the acquisition and development of biologic medicines (“antibodies”) targeting oncology will have begun, with the company already licensing three antibodies that have been fully developed and are on the market in several countries. It is PHARMIA objective to start and complete Phase 3 clinical trials of each “biosimilar” antibody targeting breast cancer, colorectal cancers, brain cancers, and several other solid tumors. Stage 2 is an important growth phase for the company.
Stage 3
In the third stage of growth, PHARMIA will focus its attention on acquiring its own manufacturing facilities in the USA for the production of Active Pharmaceutical Ingredients (APIs) and final, formulated Drug Product dosage forms. This will enable the company to totally control the whole supply chain process and also expand its portfolio of products that are, or are expected to be, in chronic short supply or suffering from ongoing quality issues when supplied from outside the USA or Europe. With its own manufacturing infrastructure in place, PHARMIA will have the capability to meet supply demand by expeditiously switching manufacturing from one product to another in the same facility with only minor process changes required. The company will expand its sterile injectable drug manufacturing capabilities and its solid dosage form (super-generics) capacity during Stage 3.
Starting with high quality but low-cost, affordable generic drugs treating deadly diseases, the second phase of grow is by employing pharmaceutical drug delivery technologies to enhance and improve the generic drug incorporated in the drug formulation as a “super-generic”. Our super-generics employ a technology called “3-D screen printing” of drugs with extended release properties and will provide a sustained drug level within the “therapeutic window” for once-a-day dosing. A single pill containing three or four medicines that can be taken once-a-day, and this approach provides the patient a lower “pill burden” and this will result in better compliance in taking the medicine and overall improved care of the patient.
The company is working on 3-D screen-printed medicines with novel dissolution and release characteristics. 3-D screen-printing technology opens up new, flexible and versatile options for the pharmaceutical industry in the manufacturing process of their products. Thousands or even millions of medical doses can be manufactured per machine per year. The 3-D screen-printing process allows for many different kinds of shapes, sizes and compositions.
We are committed to maintaining our entire business operations including the 3-D screen printing commercial manufacturing in America, Canada, and/or Europe (Ireland and Germany), and we will continue to build strong, lasting relationships with European and our Nation’s largest pharmacy chains, wholesalers, and distributors.
Essential Medicines – Affordable Prices
investorshub.ad...s/read_msg.aspx?message_id...
Dr. Joseph Sinkule
Co-Founder, Chief Executive Officer (CEO) and Director
www.pharmia-inc.com/management/
Strategic Asset Leasing Inc. Announces Cryptocurrency Launch Press Release | 10/06/2020
Strategic Asset Leasing Inc. Announces Cryptocurrency Development Press Release | 10/02/2020
Strategic Asset Leasing Inc. Enters Into MOU Press Release | 09/30/2020
Strategic Asset Leasing Inc. Announces New Subsidiary Press Release | 09/29/2020
Strategic Asset Leasing Inc. Enters Into Additional LOI Press Release | 09/25/2020
Strategic Asset Leasing Inc. Joins Open Source Projects Press Release | 09/24/2020
Stage 1
In the initial stage, PHARMIA will launch the company by acquiring MAs in Europe and ANDAs in the United States for generic products that are essential medicines in chronic short supply. PHARMIA will use 3rd parties in Germany to manufacture our oncology products and we will commercialize these “supply challenged” products which generally are older but “mainstay” life-saving medications for the treatment of cancer and infectious diseases, to include the drug shortages caused by the COVID-19 pandemic, where PHARMIA’s team has particular expertise. We will build the drug portfolio and the PHARMIA “brand name” during Stage 1.
Stage 2
In the second stage of PHARMIA’s strategic plan, the company will develop and commercialize a portfolio of novel branded “super-generics” (super-generics are “better than generics” as they have added value and are patented). To achieve this goal, PHARMIA will capitalize on its ownership of the active pharmaceutical ingredients (“API”) acquired in Stage 1, and utilize the scientific and technical development expertise of its team members to reformulate the API of those generics into patented formulations. The goal is to create novel, patentable formulations with novel and improved characteristics (such as extended release, dissolvable films and implants, multiple drug combinations in one pill, etc.) that are more patient friendly, and more easily administered. The development of a portfolio of “super-generics” during Stage 2 will be a major revenue driver going forward. This “value add” will enhance patient compliance and therapeutic outcomes, differentiating PHARMIA pipeline from the competition. Also during Stage 2, the acquisition and development of biologic medicines (“antibodies”) targeting oncology will have begun, with the company already licensing three antibodies that have been fully developed and are on the market in several countries. It is PHARMIA objective to start and complete Phase 3 clinical trials of each “biosimilar” antibody targeting breast cancer, colorectal cancers, brain cancers, and several other solid tumors. Stage 2 is an important growth phase for the company.
Stage 3
In the third stage of growth, PHARMIA will focus its attention on acquiring its own manufacturing facilities in the USA for the production of Active Pharmaceutical Ingredients (APIs) and final, formulated Drug Product dosage forms. This will enable the company to totally control the whole supply chain process and also expand its portfolio of products that are, or are expected to be, in chronic short supply or suffering from ongoing quality issues when supplied from outside the USA or Europe. With its own manufacturing infrastructure in place, PHARMIA will have the capability to meet supply demand by expeditiously switching manufacturing from one product to another in the same facility with only minor process changes required. The company will expand its sterile injectable drug manufacturing capabilities and its solid dosage form (super-generics) capacity during Stage 3.
Starting with high quality but low-cost, affordable generic drugs treating deadly diseases, the second phase of grow is by employing pharmaceutical drug delivery technologies to enhance and improve the generic drug incorporated in the drug formulation as a “super-generic”. Our super-generics employ a technology called “3-D screen printing” of drugs with extended release properties and will provide a sustained drug level within the “therapeutic window” for once-a-day dosing. A single pill containing three or four medicines that can be taken once-a-day, and this approach provides the patient a lower “pill burden” and this will result in better compliance in taking the medicine and overall improved care of the patient.
The company is working on 3-D screen-printed medicines with novel dissolution and release characteristics. 3-D screen-printing technology opens up new, flexible and versatile options for the pharmaceutical industry in the manufacturing process of their products. Thousands or even millions of medical doses can be manufactured per machine per year. The 3-D screen-printing process allows for many different kinds of shapes, sizes and compositions.
We are committed to maintaining our entire business operations including the 3-D screen printing commercial manufacturing in America, Canada, and/or Europe (Ireland and Germany), and we will continue to build strong, lasting relationships with European and our Nation’s largest pharmacy chains, wholesalers, and distributors.
Essential Medicines – Affordable Prices
investorshub.ad...s/read_msg.aspx?message_id...
Dr. Joseph Sinkule
Co-Founder, Chief Executive Officer (CEO) and Director
www.pharmia-inc.com/management/
Strategic Asset Leasing Inc. Announces Cryptocurrency Launch Press Release | 10/06/2020
Strategic Asset Leasing Inc. Announces Cryptocurrency Development Press Release | 10/02/2020
Strategic Asset Leasing Inc. Enters Into MOU Press Release | 09/30/2020
Strategic Asset Leasing Inc. Announces New Subsidiary Press Release | 09/29/2020
Strategic Asset Leasing Inc. Enters Into Additional LOI Press Release | 09/25/2020
Strategic Asset Leasing Inc. Joins Open Source Projects Press Release | 09/24/2020